Year: 2025

This information is such that the issuer is obliged to make public pursuant to Chapter 15, Section 8 of the Swedish Securities Market Act (2007:528). Stockholm, 2 December 2025 – Virtune announces that as of 4 December 2025, the issuer’s reference price provider MarketVector will carry out a technical update of the underlying price source for crypto assets used for daily NAV (“Net Asset Value”) calculations. The price source will be changed from CCData to BITA. This adjustment applies only to Virtune’s single-asset ETPs and solely entails a change of the data source used in the daily NAV (“Net Asset Value”) calculation. The change does not affect the value of the products, their structure, trading, or investors in any way. No action is required from investors. Updated final terms will be published and made available on 4 December 2025.Virtune...

Clermont-Ferrand (France), 2 December 2025 (8:45 AM CET). In line with the commitment signed on November 6, 20251, CARBIOS (Euronext Growth Paris: ALCRB) and Wankai New Materials (« Wankai »), a listed subsidiary2 of Zhink Group, the 3rd largest PET producer in China and 4th worldwide, announce the signing of the definitive agreement establishing a strategic partnership for the large-scale deployment of CARBIOS’s PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.The two companies have signed on 2 December 2025 the shareholders’ agreement for their joint venture, dedicated to the construction and operation of a first PET biorecycling plant in China, with a processing capacity of 50,000 tons of PET waste.Wankai will be the majority shareholder of this company with a 70%...

Sampo plc, stock exchange release, 2 December 2025 at 8:30 am EET Sampo plc’s share buybacks 1 December 2025 On 1 December 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  – – AQEU    – – CEUX  – – TQEX  256,343 10.14 XHELTOTAL 256,343 10.14  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on...

Männedorf, Switzerland, December 2, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced the acquisition of Wako Automation assets, including the flagship Director™ scheduling software and select hardware modules. The transaction was completed on December 1, 2025. It is Tecan’s strategic objective to expand its addressable market beyond liquid-handling-centric offerings and reinforce its leadership in laboratory automation. Advanced scheduling software enables customers to address complex workflows with greater flexibility and efficiency, with the option to seamlessly integrate Tecan’s liquid handling platforms, such as Fluent, as part of a comprehensive solution. This acquisition builds on Tecan’s successful launch of FlowPilot, a scheduling software for robotic workcells that was initially offered under license from...

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion Schlieren (Zürich), Switzerland, December 2, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced that the first patient has been enrolled in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlled, multi-center study to assess the safety and performance of MagnetOsTM compared to autograft (patient’s own bone) in patients undergoing hindfoot or ankle fusions. Subtalar fusion will be one of many surgical approaches included in the study. The ASTRA study is part of Kuros’ expanding global extremities strategy and represents the company’s continued...

The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare providers to act quickly and prevent severe complications and onward transmission. Detects and differentiates between three types of Bordetella infection that can cause similar cough symptoms, ensuring patients receive the right diagnosis at the earliest opportunity. Early diagnosis can reduce the risk of complications and severe disease in vulnerable groups such as infants and the elderly, by enabling faster, more precise care decisions.Basel, 2 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its first point-of-care test for the diagnosis of whooping cough (pertussis) and other Bordetella infections, has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments...

U.S. Registration Marks a Significant Milestone as the First Protein-Based Biofungicide of its Kind to be Approved by the EPA Ghent, BELGIUM, Dec. 02, 2025 (GLOBE NEWSWIRE) — Press release – inside information Biotalys (Euronext: BTLS) is excited to announce it has received regulatory approval from the U.S. Environmental Protection Agency (EPA) for its first biofungicide, EVOCA™*.   This product was developed using Biotalys’ AGROBODY™ technology platform and is the first protein-based biofungicide of its kind to be approved by the EPA. EVOCA is a precision biocontrol solution with a new mode of action** that targets the fungal pathogens botrytis (grey mold) and powdery mildew in high-value fruits and vegetables while minimising the risk to beneficial organisms or the environment. With this approval in hand,...

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,272,727 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $154.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 340,909 additional ADSs from the Company at the public offering price, less underwriting discounts and commissions. The gross proceeds of the offering to the Company are expected to be approximately $350.0 million before deducting underwriting discounts and commissions and offering...